Think Bioscience
Think Bioscience is a biotechnology company that uses synthetic biology to develop small-molecule drugs for historically challenging therapeutic targets. The company’s platform combines applied microbiology, enzymology, and data science to uncover novel mechanisms of biomolecular engagement, leveraging the cell as a chemical processor with capabilities that surpass digital systems. By using synthetic biology to…
Funding snapshot
About
Think Bioscience is a biotechnology company that uses synthetic biology to develop small-molecule drugs for historically challenging therapeutic targets. The company’s platform combines applied microbiology, enzymology, and data science to uncover novel mechanisms of biomolecular engagement, leveraging the cell as a chemical processor with capabilities that surpass digital systems. By using synthetic biology to identify and optimize small molecules, Think Bioscience aims to drug targets that have proven difficult or impossible to address with conventional approaches. The company focuses on targets in genomics, microbiome therapeutics, and metabolic diseases. Founded in 2019 and headquartered in Boulder, Colorado, Think Bioscience has raised approximately $26 million in Series A funding. Investors include Innovation Endeavors, Xora Innovation, AV8 Ventures, Regeneron Ventures, Janus Henderson Investors, MBX Capital, CU Healthcare Innovation Fund, Wireframe Ventures, and America’s Seed Fund. The company has approximately 31 employees.
Business model
Metabolic Diseases > Drugs > Diversified,
Genomics > Applied Genomics > Synthetic Biology
Team background
College Wise > University of California (Berkeley), Harvard Business School
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.